Vivos Partners with SoundHealth to Launch Innovative Sleep Solutions

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Feb 05 2026

0mins

VVOS-5.22%

Should l Buy VVOS?

Source: Newsfilter

Collaborative Technology Promotion: Vivos Therapeutics has partnered with SoundHealth to leverage its network of over 2,000 trained dentists and sleep healthcare providers to promote SoundHealth's Sonu® platform, aiming to enhance public awareness of airway and sleep health technologies.
Product Innovation: The Sonu®Band is the world's first FDA-cleared AI-enabled wearable device that effectively treats nasal congestion without side effects and has been recognized as one of TIME's best inventions of 2025, expected to significantly enhance Vivos' product offerings and market competitiveness.
Data-Driven Health Management: Vivos will utilize SoundHealth's CT-accurate facial scanning and voice biomarker technology to assist its clinical providers in more effectively screening and monitoring sleep disorder patients, thereby improving treatment outcomes and patient satisfaction.
Significant Market Potential: With the global sleep technology market valued at approximately $30 billion, Vivos' collaboration will drive a shift from passive monitoring to active interventions, addressing the 80% of undiagnosed sleep-disordered breathing cases, which has critical social and economic implications.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy VVOS?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on VVOS

Wall Street analysts forecast VVOS stock price to rise

3 Analyst Rating

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 1.150

Low

2.50

Averages

5.00

High

7.00

Current: 1.150

Low

2.50

Averages

5.00

High

7.00

H.C. Wainwright

NULL -> Buy

initiated

2025-11-17

Reason

H.C. Wainwright

Price Target

AI Analysis

2025-11-17

initiated

NULL -> Buy

Reason

H.C. Wainwright initiated coverage of Vivos Therapeutics with a Buy rating and $7 price target. Vivos is a commercial-stage medical device company focused on the commercialization of non-surgical treatment of maxillofacial abnormalities of the mouth and jaws that are closely associated with breathing and sleep disorders, the analyst tells investors in a research note. The firm expects the company's new business model and initiatives to drive solid sales growth in the coming years.

Alliance Global Partners

Scott Henry

Buy -> Neutral

downgrade

2025-05-20

Reason

Alliance Global Partners

Scott Henry

Price Target

2025-05-20

downgrade

Buy -> Neutral

Reason

Alliance Global Partners analyst Scott Henry downgraded Vivos Therapeutics to Neutral from Buy with a price target of $2.25, down from $5.50. The firm views the company's visibility as low pending signs of execution for its new business model, which it says is unlikely before the second half of 2025. Vivos has limited financial resources to manage this uncertainty, the analyst tells investors in a research note. Alliance points out the company's Q1 results trailed forecasts as the business model shifts from dentists to sleep specialists.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VVOS

Unlock Now

About VVOS

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

New Show to Air Tonight on Bloomberg Television

Feb 21 2026Yahoo Finance

Global Broadcast Expansion: New to The Street's latest episode will air tonight at 6:30 PM EST on Bloomberg Television, extending its reach to the U.S., MENA, and Latin America, thereby enhancing international investor engagement and broadening its audience base.
Biotech Advancements: BioVie Inc. is advancing a clinical trial for Parkinson's disease with 60 patients enrolled, expecting topline data in May 2026, which could significantly bolster its market position in the biopharmaceutical sector if successful.
Obstructive Sleep Apnea Solutions: Vivos Therapeutics Inc.'s FDA-cleared non-surgical oral appliance aims to provide a long-term solution for the estimated one billion people affected by OSA globally, with strategic growth initiatives targeting direct-to-patient markets.
Virtual Reality Market Growth: Virtuix Holdings Inc.'s Omni One platform has reported a 138% year-over-year growth in the gaming and fitness sectors, with production capacity supporting potential annual revenues of up to $100 million, indicating strong demand in both consumer and defense markets.